Profit

Biocon Launches New Hepatitis-C Drug

PUBLISHED ON: December 24, 2015 | Duration: 2 min, 22 sec

  
loading..
Kiran Mazumdar-Shaw, CMD of Biocon, said at the moment the Indian market for this new drug is approaching Rs 200 crore and it is expected to rise to Rs 500 crore.
ALSO WATCH
"Government Trusts Bureaucrats Over Businessmen": Kiran Mazumdar Shaw To NDTV

................................ Advertisement ................................

................................ Advertisement ................................